All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Conbercept
Therapeutic Area: Ophthalmology Product Name: KHB-1802
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
No reasons for the suspension of project KHB-1802 were given nor was there any mention of whether it will be resumed in the near future nor whether it will affect the registration of the drug in France.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: LY09004
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2021
Details:
LY09004 is a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection (strength 11.12mg(0.278ml)/vial).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cetirizine
Therapeutic Area: Ophthalmology Product Name: Zerviate
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
The Phase 3 trial is evaluating the safety and efficacy of ZERVIATE , first and only topical ocular formulation of the antihistamine cetirizine, for the treatment of ocular itching associated with allergic conjunctivitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Conbercept
Therapeutic Area: Ophthalmology Product Name: Lumitin
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
Conbercept is a new generation anti-VEGF fusion protein, approved and marketed in China as Lumitin®, for the treatment of retina diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: OT-702
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Shandong Boan Biological Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 30, 2020
Details:
Ocumension has been granted the exclusive right to promote and commercialize OT-702 in China. OT-702 is in phase III clinical trial and is the company's third line product to enter phase III in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NCX 470
Therapeutic Area: Ophthalmology Product Name: OT-301
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Nicox SA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Nicox and Ocumension will jointly fund the second NCX 470 Phase 3 glaucoma trial, Denali, which is expected to start by end of 2020 and will also evaluate NCX 470 ophthalmic solution, 0.1%, versus latanoprost ophthalmic solution, 0.005%.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: HLX04
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Henlius
Deal Size: $25.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement October 15, 2020
Details:
Pursuant to the Agreement, Essex and Henlius will co-develop the bevacizumab HLX04 for treatment of ophthalmic diseases such as exudative (wet) Age-related Macular Degeneration (wAMD).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
